LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems explores the development of novel therapeutics and diagnostics to improve pulmonary disease m… Read more
LIMITED OFFER
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems explores the development of novel therapeutics and diagnostics to improve pulmonary disease management, looking down to the nanoscale level for an efficient system of targeting and managing respiratory disease. The book examines numerous nanoparticle-based drug systems such as nanocrystals, dendrimers, polymeric micelles, protein-based, carbon nanotube, and liposomes that can offer advantages over traditional drug delivery systems. Starting with a brief introduction on different types of nanoparticles in respiratory disease conditions, the book then focuses on current trends in disease pathology that use different in vitro and in vivo models.
The comprehensive resource is designed for those new to the field and to specialized scientists and researchers involved in pulmonary research and drug development.
Researchers and graduate and postgraduate students in pharmaceutical sciences, biomedical sciences, biotechnology, microbiology, biochemistry, immunology, bioinformatics, translational research, and medical sciences
KD
Dr. Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over many years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.
PH
RW
MH
LP
KW